Candid Dish on New Treatments—FINAL ROUND!
MedscapeLIVE Psychiatry September 2024
Candid Dish on New Treatments—FINAL ROUND!
Faculty of the 23rd Annual Psychopharmacology Update Opine
Introduction
Welcome back, Psychiatry Newsletter Readers! As a part of our Candid Dish series, we sat down with a handful of key opinion leaders and asked them what their real thoughts are on potential up-and-coming novel treatments. This month in the final round, Part 3 of Candid Dish, they share thoughts on these treatments:
- Xylazine—solution or problem?
- Glycine transport inhibitor for cognitive deficits in schizophrenia
- New illicit drug classes (eg, nitazenes) on the horizon
- Fentanyl’s role in decreasing effectiveness of medications, and making treatment options more challenging, for opioid use disorders (OUD).
Last month’s issue featured Round 2, giving you the downlow from thought leaders on the following treatments:
- Ketamine and ECT in treatment resistant depression
- Psilocybin/psychedelics for treatment resistant depression, mood disorders, anxiety, and PTSD
- Asenapine transdermal antipsychotic
- Bupropion or theta burst transcranial magnetic stimulation
- Esmethadone for major depression
- Dexmedetomidine—sublingual alpha 2 adrenergic agonist medication for agitation
Read on in Candid Dish Final Round for candid takes on these! Huge thanks to these faculty for offering their true opinions on these treatment options.
Thank you to this month’s thought leaders for their candid thoughts and perspectives! Please contact me at colleen@cmhadvisors.com with any comments. –Colleen Hutchinson
Candid Dish on New Treatments—Final Round!
23rd Annual Psychopharmacology Update Faculty Opine
Xylazine—solution or problem (ie, wounds and ulcerations associated with its use).
Dr. Salsitz: Definitely a problem.
Dr. Goldberg: Toxin.
Dr. Nasrallah: Shelf it: there are better ways for analgesia, sedation, or anesthesia.
Glycine transport inhibitor for cognitive deficits in schizophrenia.
Dr. Nasrallah: This may finally be the breakthrough for the long-awaited treatment of cognitive impairments in schizophrenia.
Dr. Citrome: Great, if it works.
Dr. Goldberg: Good luck.
Dr. Meyer: Iclepertin is a GlyT1 inhibitor with some early phase positive data. Stay tuned.
Dr. Correll: Mechanism of action with great promise and need, but prior failures.
New illicit drug classes (eg, nitazenes) on the horizon.
Dr. Goldberg: New plague.
Dr. Salsitz: Ready or not, here come the nitazenes.
Dr. Nasrallah: Beware more needless death among the youth, and work on an effective antidote!
Fentanyl’s role in decreasing effectiveness of medications, and making treatment options more challenging, for opioid use disorders (OUD).
Dr. Salsitz: Fentanyl has thrown a monkey wrench into treatment of OUD.
Dr. Goldberg: Plague.
Dr. Nasrallah: Fentanyl in tiny amounts is pure evil, and those who smuggle it into our country to kill hundreds of thousands deserve the guillotine.
Still Need to Earn CME? Don’t Miss These Events!
23rd Annual Psychopharmacology Update
Cincinnati, OH | October 25-26, 2024
ONE MONTH AWAY! Earn up to 13.25 CME/CE Credits with your colleagues and get the latest updates in the advancements of psychiatry. Use code 40PPU for 40% off your pass!
Psychiatry Update: Focus On Psychotic and Mood Disorders | November 12, 2024
Can’t make one of our in person events? Join us virtually on November 12, 2024 and earn credits you need from our expert faculty!
Psychiatry Update 2025 | March 20-22, 2025 | Chicago, IL
Register today for the ONLY Psychiatry Update from March 20-22, 2025! Earn the credits you need, network with your colleagues, and stay current with your practice through our excellent sessions.
See What Your Colleagues Said About Psychopharmacology Update!
“It was a great refresher and also offered new and profound information I could apply to my practice”
“I liked that most of the material had practical application potential and was going to be useful in my daily practice”
“Excellent presenters, very practical and informative sessions, very well organized”
Loading ...